C X C Chemokine Receptor Cxcr Inhibitors Pipeline Insight
DelveInsight’s, “C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
C-X-C Chemokine Receptor (CXCR) Inhibitors Understanding
C-X-C Chemokine Receptor (CXCR) Inhibitors: Overview
CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as
CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells.
The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.
The companies and academics are working to assess challenges and seek opportunities that could influence C-X-C Chemokine Receptor (CXCR) Inhibitors R&D. The therapies under development are focused on novel approaches for C-X-C Chemokine Receptor (CXCR) Inhibitors.
C-X-C Chemokine Receptor (CXCR) Inhibitors Emerging Drugs Chapters
This segment of the C-X-C Chemokine Receptor (CXCR) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
C-X-C Chemokine Receptor (CXCR) Inhibitors Emerging Drugs
Motixafortide is targeting CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including PDAC. CXCR4 plays a key role in tumor growth, invasion, angiogenesis, metastasis and therapeutic resistance, and CXCR4 overexpression has been shown to be correlated with poor prognosis.
Motixafortide - BL-8040 (formerly known as BKT140 and developed by Biokine Therapeutics Ltd.) is a novel selective inhibitor of the CXCR4 chemokine receptor that is currently being developed for several indications including treatment of solid tumors, mobilization of hematopoietic stem cells (HSCs) for autologous transplantations and hematological malignancies.
Reparixin - Dompe Farmaceutici
Identified by Dompé laboratories in Italy and currently at an advanced stage (phase II) of clinical development, Reparixin is an inhibitor of CXCR1 and CXCR2 receptors. It is the first of a new class of low-molecular-weight inhibitors that can selectively modulate the receptor activity through an allosteric mechanism of action.
Further product details are provided in the report……..
C-X-C Chemokine Receptor (CXCR) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different C-X-C Chemokine Receptor (CXCR) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on C-X-C Chemokine Receptor (CXCR) Inhibitors
There are approx. 10+ key companies which are developing the C-X-C Chemokine Receptor (CXCR) Inhibitors. The companies which have their C-X-C Chemokine Receptor (CXCR) Inhibitors drug candidates in the most advanced stage, i.e. phase III include, BioLineRx.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
C-X-C Chemokine Receptor (CXCR) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses C-X-C Chemokine Receptor (CXCR) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-X-C Chemokine Receptor (CXCR) Inhibitors drugs.
C-X-C Chemokine Receptor (CXCR) Inhibitors Report Insights
- C-X-C Chemokine Receptor (CXCR) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
C-X-C Chemokine Receptor (CXCR) Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing C-X-C Chemokine Receptor (CXCR) Inhibitors drugs?
- How many C-X-C Chemokine Receptor (CXCR) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for C-X-C Chemokine Receptor (CXCR) Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the C-X-C Chemokine Receptor (CXCR) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for C-X-C Chemokine Receptor (CXCR) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?